Actuality

The first safety and immunogenicity results of the vaccine candidate Abdala (CIGB-66) were verified this Saturday 
by the independent committee for the analysis of data from the clinical study of this possible anti-COVID-19 vaccine.

The progress of the study was also highlighted by Eduardo Martínez Díaz, president of BioCubaFarma, who assured,
 in his official Twitter account, that Cuban vaccine strategies against the disease caused by SARS-COV-2 are progressing
 positively

Yesterday afternoon, the independent committee for the analysis of data from the Abdala clinical study evaluated the 
first results of safety and immunogenicity of this vaccine candidate from @CIGBCuba. 

Progress continues Specifically, Abdala, developed by the Center for Genetic Engineering and Biotechnology, and to be applied 
intramuscularly, has had constant monitoring, supervision, and evaluation by specialized agencies, including the 
National Regulatory Center for Medicines and Medical Equipment, always with favorable results.

With 200 volunteers, the first phase of the #Abdala clinical study started on December 2 will run until February 16, 
2021 and involves more than 40 health professionals including doctors, nurses and laboratory workers.

This possible vaccine and the candidate Mambisa, also conceived by the cigb, together with the Soberana series, 
from the Finlay Vaccine Institute, is the most reliable example of the scientific strength of our country and the hope that 
the population of the Island can be immunized against the deadly coronavirus that plagues the world.

Add comment